| abstract |
According to the present invention, benzamide inhibitors of the P2X receptor formula (I) are proposed, where R1 and R1 are as defined in claim 1. R3 is a heterocyclyl of formula (II) bound to the nitrogen atom (C-C), where R1 and R4 are as defined in claim 1. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, but not limited to, inflammatory diseases such as osteoarthritis and rheumatoid arthritis, allergies, asthma, chronic obstructive pulmonary disease (COPD), cancer, reperfusion or ischemia during stroke or heart attack, autoimmune diseases and other disorders. The international application was published along with an international search report. |